The Experts below are selected from a list of 20973 Experts worldwide ranked by ideXlab platform

Sara Belloli - One of the best experts on this subject based on the ideXlab platform.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer. Methods A critical and comprehensive PubMed search was performed identifying articles related to PET Imaging for hypoxia assessment in Preclinical setting from January 2007 up to January 2017. Results We have considered and described a total of 54 original articles, exploring tumour-associated hypoxia in Preclinical models. Results underlined the potential application together with the advantages and pitfalls of the use of PET in Preclinical research. Multi-target Imaging allowed to better define the relationship between hypoxia and other biological hallmarks of tumour; Imaging of hypoxia was proved as a useful tool for lesions stratification and response prediction to radiotherapy; however, cutoff indexes were identified in few studies. Hypoxia PET showed remarkable tracer delivery limitations in the study of vascular disrupting agents but suggested the potential use of PET as a marker of response or resistance to anti-angiogenics. Finally, the effect of anaesthesia on tracer kinetics and tumour oxygenation as well as perfusion dependency in tracer uptake should be carefully evaluated to avoid artefactual results. Conclusions Preclinical studies highlight the advantages and the limitations of the available hypoxia-radiotracers and their potential usefulness for the evaluation of treatments outcome and radiotherapy planning.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer.

Isabella Raccagni - One of the best experts on this subject based on the ideXlab platform.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer. Methods A critical and comprehensive PubMed search was performed identifying articles related to PET Imaging for hypoxia assessment in Preclinical setting from January 2007 up to January 2017. Results We have considered and described a total of 54 original articles, exploring tumour-associated hypoxia in Preclinical models. Results underlined the potential application together with the advantages and pitfalls of the use of PET in Preclinical research. Multi-target Imaging allowed to better define the relationship between hypoxia and other biological hallmarks of tumour; Imaging of hypoxia was proved as a useful tool for lesions stratification and response prediction to radiotherapy; however, cutoff indexes were identified in few studies. Hypoxia PET showed remarkable tracer delivery limitations in the study of vascular disrupting agents but suggested the potential use of PET as a marker of response or resistance to anti-angiogenics. Finally, the effect of anaesthesia on tracer kinetics and tumour oxygenation as well as perfusion dependency in tracer uptake should be carefully evaluated to avoid artefactual results. Conclusions Preclinical studies highlight the advantages and the limitations of the available hypoxia-radiotracers and their potential usefulness for the evaluation of treatments outcome and radiotherapy planning.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer.

Silvia Valtorta - One of the best experts on this subject based on the ideXlab platform.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer. Methods A critical and comprehensive PubMed search was performed identifying articles related to PET Imaging for hypoxia assessment in Preclinical setting from January 2007 up to January 2017. Results We have considered and described a total of 54 original articles, exploring tumour-associated hypoxia in Preclinical models. Results underlined the potential application together with the advantages and pitfalls of the use of PET in Preclinical research. Multi-target Imaging allowed to better define the relationship between hypoxia and other biological hallmarks of tumour; Imaging of hypoxia was proved as a useful tool for lesions stratification and response prediction to radiotherapy; however, cutoff indexes were identified in few studies. Hypoxia PET showed remarkable tracer delivery limitations in the study of vascular disrupting agents but suggested the potential use of PET as a marker of response or resistance to anti-angiogenics. Finally, the effect of anaesthesia on tracer kinetics and tumour oxygenation as well as perfusion dependency in tracer uptake should be carefully evaluated to avoid artefactual results. Conclusions Preclinical studies highlight the advantages and the limitations of the available hypoxia-radiotracers and their potential usefulness for the evaluation of treatments outcome and radiotherapy planning.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer.

Rosa Maria Moresco - One of the best experts on this subject based on the ideXlab platform.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer. Methods A critical and comprehensive PubMed search was performed identifying articles related to PET Imaging for hypoxia assessment in Preclinical setting from January 2007 up to January 2017. Results We have considered and described a total of 54 original articles, exploring tumour-associated hypoxia in Preclinical models. Results underlined the potential application together with the advantages and pitfalls of the use of PET in Preclinical research. Multi-target Imaging allowed to better define the relationship between hypoxia and other biological hallmarks of tumour; Imaging of hypoxia was proved as a useful tool for lesions stratification and response prediction to radiotherapy; however, cutoff indexes were identified in few studies. Hypoxia PET showed remarkable tracer delivery limitations in the study of vascular disrupting agents but suggested the potential use of PET as a marker of response or resistance to anti-angiogenics. Finally, the effect of anaesthesia on tracer kinetics and tumour oxygenation as well as perfusion dependency in tracer uptake should be carefully evaluated to avoid artefactual results. Conclusions Preclinical studies highlight the advantages and the limitations of the available hypoxia-radiotracers and their potential usefulness for the evaluation of treatments outcome and radiotherapy planning.

  • Tumour hypoxia: lessons learnt from Preclinical Imaging
    Clinical and Translational Imaging, 2017
    Co-Authors: Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Abstract:

    Purpose In tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in Preclinical models of cancer.

Adelaide Greco - One of the best experts on this subject based on the ideXlab platform.

  • Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.
    International journal of molecular sciences, 2017
    Co-Authors: Adelaide Greco, Luigi Auletta, Francesca Maria Orlandella, Paola Lucia Chiara Iervolino, Michele Klain, Giuliana Salvatore, Marcello Mancini
    Abstract:

    Thyroid cancer, which represents the most common tumors among endocrine malignancies, comprises a wide range of neoplasms with different clinical aggressiveness. One of the most important challenges in research is to identify mouse models that most closely resemble human pathology; other goals include finding a way to detect markers of disease that common to humans and mice and to identify the most appropriate and least invasive therapeutic strategies for specific tumor types. Preclinical thyroid Imaging includes a wide range of techniques that allow for morphological and functional characterization of thyroid disease as well as targeting and in most cases, this Imaging allows quantitative analysis of the molecular pattern of the thyroid cancer. The aim of this review paper is to provide an overview of all of the Imaging techniques used to date both for diagnosis and theranostic purposes in mouse models of thyroid cancer.

  • Mouse models of neurodegenerative disease: Preclinical Imaging and neurovascular component
    Brain imaging and behavior, 2017
    Co-Authors: Sandra Albanese, Adelaide Greco, Luigi Auletta, Marcello Mancini
    Abstract:

    Neurodegenerative diseases represent great challenges for basic science and clinical medicine because of their prevalence, pathologies, lack of mechanism-based treatments, and impacts on individuals. Translational research might contribute to the study of neurodegenerative diseases. The mouse has become a key model for studying disease mechanisms that might recapitulate in part some aspects of the corresponding human diseases. Neurodegenerative disorders are very complicated and multifactorial. This has to be taken in account when testing drugs. Most of the drugs screening in mice are very difficult to be interpretated and often useless. Mouse models could be condiderated a ‘pathway models’, rather than as models for the whole complicated construct that makes a human disease. Non-invasive in vivo Imaging in mice has gained increasing interest in Preclinical research in the last years thanks to the availability of high-resolution single-photon emission computed tomography (SPECT), positron emission tomography (PET), high field Magnetic resonance, Optical Imaging scanners and of highly specific contrast agents. Behavioral test are useful tool to characterize different animal models of neurodegenerative pathology. Furthermore, many authors have observed vascular pathological features associated to the different neurodegenerative disorders. Aim of this review is to focus on the different existing animal models of neurodegenerative disorders, describe behavioral tests and Preclinical Imaging techniques used for diagnose and describe the vascular pathological features associated to these diseases.

  • Advances in molecular Preclinical therapy mediated by Imaging.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the, 2016
    Co-Authors: Adelaide Greco, Sandra Albanese, Luigi Auletta, Marco Salvatore, Flavia De Carlo, Candace M. Howard, Pier Paolo Claudio
    Abstract:

    Several advances have been made toward understanding the biology of cancer and most of them are due to robust genetic studies that led to the scientific recognition that although many patients have the same type of cancer their tumors may have harbored different molecular alterations. Personalized therapy and the development of advanced techniques of Preclinical Imaging and new murine models of disease are emerging concepts that are allowing mapping of disease markers in vivo and in some cases also receptor targeted therapy. Aim of this review is to illustrate some emerging models of disease that allow patient tumor implantation in mice for subsequent drug testing and advanced approaches for therapy mediated by Preclinical Imaging. In particular we discuss targeted therapy mediated by high frequency ultrasound and magnetic resonance, two emerging techniques in molecular Preclinical therapy.

  • Ultrasound biomicroscopy in small animal research: applications in molecular and Preclinical Imaging.
    Journal of biomedicine & biotechnology, 2011
    Co-Authors: Adelaide Greco, Marcello Mancini, Sara Gargiulo, Matteo Gramanzini, Pier Paolo Claudio, Arturo Brunetti, Marco Salvatore
    Abstract:

    Ultrasound biomicroscopy (UBM) is a noninvasive multimodality technique that allows high-resolution Imaging in mice. It is affordable, widely available, and portable. When it is coupled to Doppler ultrasound with color and power Doppler, it can be used to quantify blood flow and to image microcirculation as well as the response of tumor blood supply to cancer therapy. Target contrast ultrasound combines ultrasound with novel molecular targeted contrast agent to assess biological processes at molecular level. UBM is useful to investigate the growth and differentiation of tumors as well as to detect early molecular expression of cancer-related biomarkers in vivo and to monitor the effects of cancer therapies. It can be also used to visualize the embryological development of mice in uterus or to examine their cardiovascular development. The availability of real-time Imaging of mice anatomy allows performing aspiration procedures under ultrasound guidance as well as the microinjection of cells, viruses, or other agents into precise locations. This paper will describe some basic principles of high-resolution Imaging equipment, and the most important applications in molecular and Preclinical Imaging in small animal research.